Research Dose Ranges Preclinical animal studies: 110 mcg/kg (nanogram to microgram range) once or twice daily Extrapolated human equivalent range commonly discussed in clinical literature: 200500 mcg/day Human pilot IV data: doses up to 20 mg were tolerated without adverse effects in two healthy adults (Lee & Burgess, 2025) though this is far above typical outpatient dosing Protocol: Musculoskeletal / Connective Tissue Healing For tendon, ligament, or muscle injury recovery, the standard approach in clinical functional medicine practice involves: SubQ injection at 200500 mcg once daily , injected near (not into) the injury site Cycle length: typically 48 weeks , with reassessment Often combined with TB-500 (thymosin beta-4) for synergistic tissue remodeling the BPC+TB stack Best results seen alongside physical therapy, not as a substitute for it Protocol: Gut and GI Mucosal Healing For IBD, gut permeability, NSAID damage, or H
Reported Effects Mild and infrequent effects reported in research include transient nasal irritation (intranasal administration), mild headache, and short-lived changes in alertness
Mass Spectrometry Verification Mass spectrometry confirms molecular identity and structural accuracy
Work in a clean, low-traffic area away from open windows, fans, or air vents that could carry airborne particles onto your work surface
Modulation of Inflammation By balancing immune responses, BPC-157 reduces destructive inflammation while maintaining tissue protection
